Investors

News & Publications

News Releases

News Releases

November 27, 2019
Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference
NEW HAVEN, Conn. , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the 31 st Annual
November 21, 2019
Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors
Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience NEW HAVEN, Conn. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Laurie
November 6, 2019
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
NEW HAVEN, Conn. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a price of $22.00
November 6, 2019
Arvinas, Inc. Announces Proposed Offering of Common Stock
NEW HAVEN, Conn. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an underwritten public offering of $90.0 million of shares of its common stock.  In
Displaying 1 - 10 of 28